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Introduction
One-third of antiretroviral treatment (ART)-eligible patients are estimated to be lost to care 
between communicating ART eligibility and initiating ART1 – the so-called ‘third stage’ of pre-ART 
care2 – increasing the risk of morbidity and mortality.3 Whilst patient education and adherence 
counselling are recommended to improve long-term adherence,4,5 lengthy preparation processes 
before starting ART cause delays during this pre-ART stage, contributing to high losses to care.6,7
In practice, there are wide-ranging approaches to patient ART preparation within the South African 
public sector.6 In 2012, the South African National Department of Health released a circular that 
recommended fast-tracking patients onto ART without unnecessary delay. It further recommended 
that patients with CD4 counts < 200 cells/mm3 and pregnant women be started on the same day 
that ART eligibility is ascertained. Some facilities now provide minimal ART preparation owing to 
prioritising fast-tracking, whilst others continue to require prior attendance of 3 (and sometimes 
more when co-infected with TB) education and adherence counselling sessions.
Médecins Sans Frontières (MSF), along with its partners (see acknowledgements), developed a 
revised approach to ART initiation counselling which supports rapid initiation without failing 
to adequately prepare a patient for lifelong adherence to treatment, including those who are 
co-infected with TB or pregnant. The overall aim of the revised approach is to reduce the loss 
of patients prior to ART initiation without increasing losses post ART initiation or reducing 
adherence amongst such patients.
The aim of the present study is to describe the intervention and determine the retention 
outcomes during the third stage of pre-ART care and post ART initiation of patients who 
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Background: Lengthy antiretroviral treatment (ART) preparation contributes to high losses 
to care between communicating ART eligibility and initiating ART. To address this shortfall, 
Médecins Sans Frontières implemented a revised approach to ART initiation counselling 
preparation (integrated for TB co-infected patients), shifting the emphasis from pre-initiation 
sessions to addressing common barriers to adherence and strengthening post-initiation 
support in a primary healthcare facility in Khayelitsha, South Africa.
Methods: An observational cohort study was conducted using routinely collected data for 
all ART-eligible patients attending their first counselling session between 23 July 2012 and 30 
April 2013 to assess losses to care prior to and post ART initiation. Viral load completion and 
suppression rates of those retained on ART were also calculated.
Results: Overall, 449 patients enrolled in the study, of whom 3.6% did not return to the facility 
to initiate ART. Of those who were initiated, 96.7% were retained at their first ART refill visit 
and 85.9% were retained 6 months post ART initiation. Of those retained, 80.2% had a viral 
load taken within 6 months of initiating ART, with 95.4% achieving viral load suppression.
Conclusions: Adapting counselling to enable rapid ART initiation is feasible and has the 
potential to reduce losses to care prior to ART initiation without increasing short-term losses 
thereafter or compromising patient adherence.
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underwent this model of counselling. Secondary outcomes 
include viral load completion and suppression rates of 
those retained on ART.
Methods
Study design
This was an observational cohort study using routinely 
collected data.
Study setting
Khayelitsha is a peri-urban township on the outskirts of Cape 
Town, South Africa. It has a population of approximately 
500 000 with high burdens of both HIV and TB. In 2011, 
the antenatal HIV prevalence was 34.3%8 and the TB case 
notification rate at least 1500 per 100 000 population per 
year.9
The study site (Kuyasa Clinic) is a general primary healthcare 
facility run by the City of Cape Town’s Health Department. 
HIV and TB related services include: HIV counselling and 
testing (HCT), pre-ART, ART initiation, ART management, 
ART adherence clubs10 and both drug-susceptible and drug 
resistant TB services. According to 2013/2014 records, the 
clinic tests each month approximately 466 patients for HIV 
(2014), initiates approximately 50 patients on ART (2014), 
starts TB treatment for approximately 37 patients (2013) and 
had 2766 ART patients retained in care at the end of June 2014, 
with 772 (28%) receiving their treatment and care through 
ART adherence clubs.
Antiretroviral treatment management
In South Africa, ART eligibility is determined by World 
Health Organization clinical staging combined with CD4 cell 
count. Western Cape HIV clinical guidelines provided that, 
from August 2011, patients with WHO stage 4 disease or 
those with a CD4 count < 350 cells/mm3 were eligible to start 
ART. Patients are due for their first and second viral loads at 
4 and 12 months on ART respectively.
Antiretroviral treatment preparation education 
and counselling
Prior to July 2012, the ART initiation counselling 
model in place at Kuyasa Clinic consisted of three 
counselling sessions, scheduled at weekly intervals 
after communication of ART eligibility, followed by 
ART initiation. Co-infected TB/HIV patients were 
also required to undergo 3 TB counselling sessions, 
which at the time were not integrated within the ART 
preparation counselling process. Where a clinician 
indicated a need to rapidly initiate HIV or TB treatment 
for clinical reasons, counselling was condensed into 
fewer sessions. Counsellors were not trained on how 
to appropriately condense sessions – specifically on 
what information remained pertinent and necessary. 
Counselling was provided by lay counsellors, employed 
by a nongovernmental organization (NGO) funded by 
the Western Cape’s Department of Health (WCDoH). The 
counsellors were trained by the WCDoH’s AIDS Training, 
Information and Counselling Centre (ATICC) according 
to Egan’s ‘skilled helper’ model of counselling.11
From July 2012, MSF supported the implementation of 
a revised ART initiation counselling model at Kuyasa 
Clinic. In summary, the lay counsellor provides a total 
of four counselling sessions: 1 session prior to ART 
initiation (‘session 1’) on the date when ART eligibility is 
communicated to the patient, 1 session on the day of ART 
initiation (‘session 2’), and two sessions post ART initiation 
(’sessions 3 and 4’) on subsequent clinic appointment/ART 
refill dates. Where the patient indicates at the end of session 1 
that he/she is not ready to start, a further ‘not ready to start’ 
session is scheduled (’session 1C’) that specifically aims to 
work through patient-identified barriers to initiating ART. 
Where it is appropriate for clinical reasons to initiate ART on 
the day that ART eligibility is assessed, it is possible to carry 
out the first two sessions on the same day. Where a patient 
is diagnosed with TB and HIV, one additional counselling 
session is added prior to session 1 to prepare the patient 
for starting and adhering to TB treatment. Each counselling 
session is designed to take 12 min – 18 min. Figure 1 outlines 
session timing. Where a patient is not able to return to the 
clinic 2 weeks after ART initiation, sessions 3 and 4 are 
combined and provided at the first ART refill date, which is 
28 days after ART initiation.
The counselling approach is based on the Life Steps 
intervention to HIV medication adherence12,13 in which 
cognitive behavioural, problem solving, and motivational 
interviewing techniques are used to enhance motivation 
and assist HIV-positive patients to develop better skills for 
adhering to HIV treatment. This model has shown favourable 
results in different settings.14
The Life Steps model was simplified and adapted to barriers 
and adherence planning requirements identified by MSF 
through its work with patients attending a second-line failure 
ART, antiretroviral treatment.
FIGURE 1: Timing of counselling sessions.
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clinic in Khayelitsha.15,16 Patient education is limited to essential 
information to initiate ART and TB treatment, supported 
through the use of a visual aid and a take-home leaflet. The 
14 most common barriers to start ART and adherence (Box 1) 
are addressed with all patients and are documented in each 
patient’s adherence plan. The approach focuses on creating 
a patient-oriented motivation for commitment to lifelong 
treatment.
Session guides were developed, defining the content to 
address per session, and served as a working tool for both 
counsellor and counsellor supervisor. Both counsellors were 
trained, and fidelity to the intervention was assured through 
regular supervision by observation of sessions using a 
standardised observation checklist, and review of patients’ 
adherence plans and counsellors’ paper registers recording 
patients enrolled and counselling sessions provided. This 
supervision was performed by an NGO counsellor supervisor 
who covered a number of clinics and MSF staff.
For further details on the model, including session plans and 
tools, see ART/TB/PMTCT Initiation counselling model 
report and toolkit at http://bit.ly/197VDfb.
Study participants
From 23 July 2012 to 30 April 2013, all HIV-positive patients 
found to be eligible for ART initiation who attended session 1 
were enrolled in the study.
Data collection and analysis
All data were collected (other than viral load results) at the 
end of January 2014, providing a minimum of 9 months of 
follow-up. Viral load data were collected on 30 September 
2014. Variables collected included age, sex, CD4 count, TB at 
ART start, TB treatment start date, attendance of counselling 
sessions, ART initiation date, last visit date to the clinic for 
ART refill, reported transfers and deaths, and dates of first 
viral load and first viral load outcome.
Study outcomes were time taken and retention from session 
1 to ART initiation, short-term retention on ART at 28 days 
(first ART refill) and 6 months (183 days) post ART initiation, 
viral load completion and suppression within 6 months of 
ART initiation, and viral load suppression at first viral load.
We defined retention at 1 month and 6 months as those 
patients whose last visit to the clinic or documented transfer 
date was more than 28 days and 6 months after the date of 
ART initiation. Viral load suppression was defined as < 400 
copies/mL.
Descriptive analyses were done in STATA Version 13.17
Ethics approval
Ethics approval was obtained from the University of Cape 
Town Human Research Ethics Committee. Permission to do 
the study was obtained from the City of Cape Town research 
committee.
Results
A total of 449 patients attended session 1 from 23 July 2012 
to 30 April 2013, thereby enrolling in the study, of whom 
300 (66.8%) were female and 137 (30.5%) of whom had TB at 
enrolment. Median age was 31 years (interquartile range [IQR] 
26–37 years) and median CD4 count 242 cells/mm3 (IQR 147 
cells/mm3 – 308 cells/mm3) at enrolment. A further breakdown 
of age and CD4 count categories is set out in Table 1.
Figure 2 presents a summary of counselling session 
completion. Of those patients who enrolled in the study, 427 
(95.1%) completed session 2, of whom two did not proceed to 
initiate ART. Session 3 was completed by 392 (92.2%) of those 
who completed session 2 and initiated ART and 329 (86.4%) 
of those patients who returned to the study site for their 
28-day ART refill, completed session 4.
Figure 3 details retention in care from enrolment to 6 months 
post ART initiation. ART was initiated by 433 (96.4%) 
BOX 1: Adherence steps addressed in antiretroviral treatment initiation 
counselling model.
14 adherence steps:
Step 1: Understanding HIV (and TB)
Step 2: Identify support system
Step 3: Planning future appointments
Step 4: Readiness to start treatment
Step 5: Creation of a medication schedule
Step 6: Managing missed doses
Step 7: Reminder strategies
Step 8: Storing medication and extra doses
Step 9: Dealing with side-effects
Step 10: Planning trips
Step 11: Dealing with substance use
Step 12: Communication with treatment team
Step 13: Learning from mistakes
Step 14: Making goals: suppressed viral load (and TB continuation phase)
TABLE 1: Demographic and clinical characteristics of patients included in study 
at enrolment.
Characteristics Number %
Gender
Male 149 33.2
Female 300 66.8
Age (in years)
Median† 31 -
14–18 19 4.2
19–25 80 17.8
26–39 272 60.6
40–54 75 16.7
> 55 3 0.7
CD4 count‡ (cell/mm3)
Median§ 242 -
≤ 50 33 7.4
51–200 131 29.6
201–350 224 50.6
351–500 36 8.1
> 500 19 4.3
N = 449.
†, IQR 26–37; ‡, missing three patients’ CD4 counts; §, IQR 147–308.
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patients. Median time to the start of ART for all enrolled 
patients from session 1 was 5 days (IQR 2–14 days). Forty-
nine (11%) patients started ART on the same day as session 
1, indicating fast-tracking for clinical reasons including 
pregnancy, whilst 32 (7%) took more than 28 days to start (see 
further breakdown of time to ART start in Table 2 below). 
Patients with a concurrent TB diagnosis took a median of 18 
days (IQR 14–29 days) from start of TB treatment to initiate 
ART. After excluding patients with documented transfers 
to other facilities, 412 (96.7%) and 353 (85.9%) patients were 
retained respective at 1 and 6 months post ART initiation.
The median time to first viral load was 4.4 months (134.5 
days [IQR 114–174 days]). Of those patients retained at the 
study clinic, 283 (80.2%) had a viral load taken within 6 
months of initiating ART, with 270 (95.4%) achieving viral 
load suppression. By 30 September 2014, 342 (96.9%) had 
their first viral load taken, with a 94.4% suppression rate. See 
Table 2 for a further breakdown of time to first viral load.
Discussion
By adapting ART initiation education and counselling to 
expedite the start of treatment, whilst addressing common 
barriers to patients’ readiness to start ART, only 3.6% of 
patients were lost from care between their first counselling 
session and ART initiation. The proportion of patients 
initiating ART after being informed of their eligibility for 
treatment is substantially higher than estimates reported 
previously in South Africa and elsewhere in the region.1,18 
Our findings are comparable to the outcomes of a randomised 
controlled trial by Rosen et al. which reported pre-ART losses 
when rapid (2%) versus standard ART initiation (28%) took 
place.19
Reducing losses to care prior to ART initiation carries a 
potential risk of increased losses immediately after ART 
start, if patients are uncomfortable with starting quickly or 
are insufficiently prepared. Our study found limited losses 
Session 1
449
Session 2
427 (95.1%)
Iniated ART
425
Session 3
392 (92.2%)
Retained at study site at 1 month
381
Session 4
329 (86.4%)
ART, antiretroviral treatment.
FIGURE 2: Counselling session completion.
Enrolled in counselling intervention
23 July 2012 – 30 April 2013
449 
1-month retention outcomes
(Excluded: Documented transfers out: 7 [1.6%])
Initiated ART
433 (96.4%)
6-month retention outcomes
(Excluded: Documented transfers out: 22 [5.1%])
1st VL: 342 (96.9%)
High VL: 19 (5.6%)
Suppressed VL: 323 (94.4%)  
1st VL within 6 months of ART start: 283 (80.2%)
High VL: 13 (4.6%)
Suppressed VL: 270 (95.4%)  
Reported deaths: 4 (1%)
Lost to follow-up: 54 (13.1%)
Retained in care: 353 (85.9%)
Reported deaths: 3 (0.7%)
Lost to follow-up: 11 (2.6%)
Retained in care: 412 (96.7%) 
ART, antiretroviral treatment; VL, viral load.
FIGURE 3: Retention and viral load outcomes.
TABLE 2: Time from enrolment (session 1) to antiretroviral treatment start and first viral load.
Category Subcategory Number Percentage 
Enrolment (session 1) to antiretroviral treatment start† Median (IQR) 5 days (IQR 2–14 days) -
Same day 49 11
1–7 days 224 52
8–14 days 55 13
15–21 days 47 11
22–28 days 16 4
> 28 days 32 7
Counselled after antiretroviral treatment start 5 1
Restarted (treatment interrupters from other antiretroviral treatment sites) 5 1
Time from antiretroviral treatment start to first viral load‡ Median days (IQR) 134.5 (114–174) -
≤ 6 months 283 80.2
6–9 months 33 9.3
9–≤ 13 months 19 6.7
> 13 months 7 2.0
No viral load taken by 30 September 2014 11 3.1
†, N = 433; ‡, N = 353.
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immediately after ART start, with 2.6% of those initiated 
not returning for their 1-month ART refill appointment. At 
6 months after ART initiation, 85.9% of patients were 
retained, which is comparable to elsewhere in South Africa20 
and sub-Saharan Africa.21,22 Whilst cohorts that started ART 
prior to 2008 in Khayelitsha were reported to have higher 
6-month retention outcomes,23 a recent study reporting on 
MSF cohorts has shown higher losses to care in more recently 
initiated cohorts, with the 2011 cohort retaining 85.5% (95% 
CI 84.5% – 86.4%) at this time point.22 It is worth noting that 
it may not be appropriate to compare retention reported in 
older versus more recently initiated cohorts; this point is due 
to increasing unaccounted-for self-transfers hidden within 
the lost to follow-up (LTFU) outcome24 and a bias towards 
better retention outcomes in older cohorts introduced by 
longer follow-up times, which allow transient treatment 
interrupters to return to care.25
It took less than a week for patients to initiate ART from 
starting ART preparation counselling. Whilst there is 
extensive evidence on the delay between ascertaining ART 
eligibility (date of CD4 count) and initiating ART, with a 
recent systematic review reporting a range of 22–108 days,18 
we could find no routine programme evidence specifically 
measuring the time from starting ART preparation 
counselling to ART initiation.
High rates of both viral load completion and suppression 
were achieved. These were higher than those previously 
reported for ART patients in Khayelitsha.23 Focusing the 
ART initiation counselling sessions on making practical 
plans to overcome the most commonly experienced barriers 
to maintaining good treatment adherence, together with 
educating and motivating patients towards the goal of 
achieving an undetectable viral load, might have contributed 
to these high completion and suppression rates.
The use of motivational interviewing has been recommended 
to ensure behaviour change related to ART adherence26 but, in 
resource-limited settings, major challenges exist to make lay 
counsellors proficient in using these more complex counselling 
techniques.27,28 Whilst this model was based on principles of 
motivational interviewing, by engaging with all patients on 
planning around the same common barriers to adherence, 
the counselling model did not require lay counsellors to use 
more complex counselling techniques. Barriers to address 
with patients were predefined, and each adherence barrier 
was addressed in a standardised way by setting the goal, 
identifying the possible barriers to reaching that goal, and 
concluding on a plan per adherence barrier. Our experiences 
with the ART initiation counselling model suggest that this 
may provide a feasible approach to enhancing the counselling 
skills of lay counsellors, whilst taking their limitations into 
account. The present study is not comparable with a recently 
published study in South Africa that found no difference in 
patient adherence or virological suppression outcomes when 
assessing those who received only didactic education with 
those who received both didactic education and counselling 
utilising motivational interviewing skills.29 Our study was 
carried out in an operational setting, provided a maximum of 
one session prior to the day of ART initiation, sessions were 
considerably shorter in length, and sessions were carried out 
by existing lay counsellors only, and not nursing staff.
Our results should be considered in the light of the following 
strengths and limitations: the principle strength of the study 
is demonstration of feasibility within an operational setting 
utilising existing lay counselling staff. There were a number 
of limitations, the first three relating to the study constraint 
of limited pre-ART routine data. Firstly, we were unable to 
provide a comparison group as a result of poor routine pre-
ART data collection prior to implementation of the revised 
ART initiation counselling model, including attendance 
of ART counselling preparation sessions. Secondly, the 
date of baseline CD4 counts was not accurately captured, 
often reflected as the same date as ART initiation, limiting 
our capacity to calculate length of time from eligible CD4 
count to ART start. Thirdly, whilst the intervention was 
designed for patients to attend session 1 immediately 
after being informed of their ART eligibility, we were 
unable to verify the date on which such communication 
took place. Further limitations should be noted: during 
the evaluation period described by the present study, the 
counselling model had not yet been specifically adapted 
for pregnant women initiated on ART. Whilst these women 
were enrolled in the study and accounted for some of the 
same-day ART initiations with high CD4 counts, we were 
unable to reliably identify those starting ART for PMTCT 
purposes. Their inclusion in the study cohort might have 
increased overall short-term losses to care as reported 
elsewhere.30,31 Lastly, despite basic interventions to ensure 
fidelity, no specific data were collected to report on fidelity 
to the piloted model.
The present study highlights useful directions for future 
research. Most importantly, further evidence is required to 
determine the optimal ART initiation counselling model that 
can feasibly be implemented in settings with lay counsellors, 
who have no formal professional or paraprofessional degree 
in counselling and high numbers of ART patients. These 
models should ideally also evaluate pre- and post ART 
retention outcomes. To provide a better understanding of the 
counselling model, components such as timing, counselling 
provider, session length, content and measures to ensure 
fidelity to the intervention should always be described. In 
addition to counselling model research, more studies are 
required that report on the extent of delays and losses to care 
attributable to lengthy ART preparation processes prior to 
ART initiation. Lastly, whilst there is substantial evidence on 
optimal timing for starting ART after TB treatment initiation 
from a clinical perspective,32,33 competing risk analysis would 
benefit from studies reporting on losses to care caused by 
delaying ART initiation for TB co-infected patients.
Conclusion
Adapting initiation education and counselling to enable 
the rapid start of ART, by addressing common barriers to 
http://www.sajhivmed.org.za doi:10.4102/sajhivmed.v16i1.367
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adherence and strengthening post-initiation support, is 
feasible. It has the potential to reduce losses to care prior to 
ART initiation without increasing short-term losses thereafter 
or compromising patient adherence. ART programmes 
should consider adjusting their ART initiation counselling 
to limit delays but ensure that fast-tracking does not result 
in patients receiving inadequate adherence support with 
possible negative long-term consequences.
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